Hikma Pharmaceuticals PLC and Cipla Ltd. have resolved their legal disputes with Pfizer Inc. concerning the development of generic versions of Pfizer’s Vyndamax, a drug used to treat a rare heart condition. This settlement marks a significant moment in the pharmaceutical industry, reflecting the ongoing challenges and negotiations surrounding drug patent rights. Vyndamax, approved by…
In an upcoming U.S. Supreme Court case set for Wednesday, the “skinny label” dispute over generic drugs will take center stage. The controversy revolves around the extent to which generic drug manufacturers can provide limited labeling to avoid infringing on brand-name drug patents. This pivotal case will feature top-tier legal talent, including an experienced patent…
The U.S. Supreme Court has decided not to review the sanctions imposed on attorney William Ramey, affirming the lower court’s ruling that he and his client brought a frivolous patent lawsuit against Google. This denial upholds the $255,000 penalties initially levied by a California judge, who criticized the lawsuit’s merit. Ramey had contended that the…
Google has petitioned the U.S. Supreme Court regarding a controversial policy by the U.S. Patent and Trademark Office (USPTO) that relies on the age of patents when denying requests for review. This move by Google challenges what it describes as an “unprecedented and unsupported action” that oversteps the USPTO’s authority. The high stakes of this…
A Texas federal jury recently exonerated Cisco Systems Inc. from claims that it infringed on three patents held by EireOg Innovations Ltd. The patents in question were related to methods of managing computer chip components. This verdict marks a significant win for the tech giant, effectively nullifying accusations that threatened its operations. The jury reached…
CureVac, a subsidiary of BioNTech, has initiated a legal battle against Moderna, asserting that its COVID-19 vaccine infringes on several of its patents related to messenger RNA (mRNA) technology. The German company alleges that Moderna has “exploited” its innovations without proper licensing agreements, creating tension in the competitive field of vaccine development. Moderna’s vaccine, one…
As the U.S. Supreme Court prepares to hear oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc. on April 29, legal professionals across various sectors are closely observing the proceedings. The dispute centers on induced infringement, specifically related to “skinny labels” and their role in patent litigation. “Skinny labels” allow generic drug manufacturers…
In a notable development, U.S. District Judge Alan Albright has recused himself from a case involving Verizon’s legal dispute with a patent holding company. The case centers around claims that the company attempted to avoid a substantial attorney fee award exceeding $500,000. This decision follows revelations of Judge Albright’s past communications with the patent holder,…
The U.S. Supreme Court is set to tackle a pivotal case concerning the use of so-called “skinny labels” in the pharmaceutical industry. Scheduled for arguments on Wednesday, the case centers on whether Teva Pharmaceuticals can be held liable for patent infringement after marketing a generic version of the blockbuster heart drug carvedilol. The outcome could…
The U.S. Supreme Court recently declined to hear an appeal from attorney William Ramey, who was contesting $255,000 in sanctions levied against him and his client. These sanctions were the result of a patent lawsuit against Google deemed frivolous by a California court. Ramey’s appeal argued that the lower court used an incorrect legal standard…
In an era of rapidly evolving technological advancements, Questel, a Paris-based intellectual property software and services company, has announced the launch of QaECTER, an AI model developed for semantic patent retrieval. The company claims that this innovative model excels across various metrics, outperforming competing systems even when they are significantly larger in scale. The QaECTER…
U.S. District Judge Alan Albright, known for transforming the Western District of Texas into a hub for patent litigation, has left a significant docket of cases behind for his colleagues to manage after stepping down from handling new patent cases. Albright’s decision to relinquish his role in this area has led to a considerable distribution…
As artificial intelligence continues to integrate into the legal landscape, corporate legal teams and law firms are grappling with its implications for intellectual property protection. The fusion of AI and human talent presents both opportunities and challenges, particularly as traditional IP frameworks struggle to keep pace with technological innovations. The evolving capabilities of AI in…
U.S. District Judge Alan Albright has announced that he will be stepping down from his position at the Western District of Texas at the end of summer, aiming to return to patent litigation work. Albright’s time as a judge has been marked by significant influence over the patent landscape in the United States. As he…
U.S. District Judge Alan Albright announced his departure from the Western District of Texas, marking the close of an influential eight-year tenure in shaping U.S. patent law. Renowned for transforming the district into a pivotal venue for patent litigation, Albright reflected on his term and shared insights in a recent discussion. His forthcoming return to…
In a recent development in the legal battle between biotechnology companies, Natera has formally requested that the U.S. Supreme Court dismiss CareDx’s petition seeking review of a Third Circuit decision. This decision previously overturned a $45 million jury verdict related to CareDx’s false advertising claims against Natera. CareDx argued that the Third Circuit’s ruling created…
In a critical development for patent litigation, the Federal Circuit has rejected TQ Delta’s request to revisit the damages award in its case against CommScope Holding Co. The decision, delivered on Friday, upheld the original calculation that resulted in an $11.1 million damages award for TQ Delta, thereby curtailing any possibility of a new damages…
Pfizer Inc. and Dexcel Ltd., an Israeli pharmaceutical company, have agreed to discontinue a legal battle concerning the heart drug Vyndamax. This agreement was reached just before the case was set to proceed to a bench trial. Pfizer’s legal action aimed to prevent Dexcel from manufacturing a generic version of Vyndamax, a medication designed for…
The U.S. Supreme Court is set to hear Hikma Pharmaceuticals USA v Amarin Pharma, a case delving into the intricacies of pharmaceutical patent law. The dispute centers on the interactions between Amarin, the manufacturer of the cardiovascular medication Vascepa, and Hikma Pharmaceuticals, which produces a generic substitute. At its core, this case questions the threshold…
In recent years, U.S. District Judge Alan Albright from the Western District of Texas emerged as a pivotal figure in patent litigation. Known for attracting a disproportionate number of patent cases to his courtroom, his approach triggered significant debate and mixed reactions across legal circles. While initially criticized by the Federal Circuit for concentrating patent…
U.S. District Judge Alan Albright’s impact on patent litigation has left a substantial imprint on the legal landscape. Serving in the Western District of Texas, Judge Albright rose to prominence in 2019, attracting considerable attention for his management of patent cases. His court became a sought-after venue for patent disputes, prompting discussions on judicial efficiency…
In the latest series of decisions, U.S. Patent and Trademark Office Director John Squires has issued a bulk order granting five inter partes reviews (IPRs) under the America Invents Act, while denying four others. The decisions were rendered with minimal commentary, a strategy that has become increasingly common in recent practice. This approach is part…
The Federal Circuit recently upheld the U.S. International Trade Commission’s decision in favor of Keysight Technologies Inc., absolving it of allegations made by Centripetal Networks LLC regarding patent infringement in the cybersecurity domain. This ruling includes a notable finding that invalidates several claims within one of Centripetal’s patents. The decision signals significant implications for ongoing…
The U.S. Patent and Trademark Office (USPTO) is experiencing a significant transition as its acting leader, Drew Hirshfeld, prepares to depart. His role in steering the agency’s patent division has been pivotal, and his imminent retirement marks an important shift. Hirshfeld, who stepped in as the acting commissioner, will be succeeded by a deputy commissioner…
Corcept Therapeutics Inc. is urging the full U.S. Court of Appeals for the Federal Circuit to reconsider a panel’s decision that upheld a lower court’s ruling in favor of Teva Pharmaceuticals USA Inc. regarding the production of a generic version of Korlym, a drug used to treat Cushing’s syndrome. Corcept contends that the panel improperly…